Are Charles Farkas’s CONMED (CNMD) transactions open-market buys or compensation-related?

The reported transactions are compensation-related rather than open-market trades. They involve an RSU grant of 5,772 units and the exercise of 668 RSUs into common shares, both tied to CONMED’s 2025 Long-Term Incentive Plan rather than market purchases.

CONMED director exercises RSUs, gains 668 shares

CONMED Corp director Charles Farkas reported routine equity compensation activity.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CONMED Corp director Charles Farkas reported routine equity compensation activity. On June 1, 2026, he received a grant of 5,772 RSUs, each representing a right to one share of common stock under the Company’s 2025 Long-Term Incentive Plan, generally vesting 100% after one year. On June 2, 2026, he exercised 668 RSUs into the same number of CONMED common shares at a stated price of $0.00 per share, bringing his direct common stock holdings to 15,527 shares. After the exercise, the specific 668-unit RSU award shows no remaining balance, while the newer 5,772-unit grant reflects his continuing derivative position.

Insider Trade Summary

668 shares exercised/converted

Exercise 3 txns

Insider Farkas Charles

Role Director

Type	Security	Shares	Price	Value
Exercise	RSUs (Restricted Stock Units)	668	$0.00	$0.00
Exercise	Common Stock	668	$0.00	$0.00
Grant/Award	RSUs (Restricted Stock Units)	5,772	$0.00	$0.00

Holdings After Transaction: RSUs (Restricted Stock Units) — 5,772 contracts (Direct); Common Stock — 15,527 shares (Direct)

Footnotes (2)

F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.

Key Figures

RSU grant: 5,772 units RSUs exercised: 668 units Shares received on exercise: 668 shares +3 more

6 metrics

RSU grant 5,772 units Restricted stock units granted on June 1, 2026

RSUs exercised 668 units RSUs converted to common stock on June 2, 2026

Shares received on exercise 668 shares Common stock from RSU exercise at $0.00 per share

Shares owned after transactions 15,527 shares Direct common stock holdings following June 2, 2026 exercise

RSU vesting schedule 100% after one year Vesting terms under 2025 Long-Term Incentive Plan

RSU expiration June 1, 2036 Expiration date for 5,772-unit RSU grant

Key Terms

Restricted Stock Units, 2025 Long-Term Incentive Plan, contingent right, vests 100% after a one year period

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2025 Long-Term Incentive Plan financial

"subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan"

contingent right financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock"

vests 100% after a one year period financial

"with the RSUs generally vesting 100% after a one year period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CONMED (CNMD) director Charles Farkas report?

Director Charles Farkas reported an equity grant and an RSU exercise. He received 5,772 restricted stock units on June 1, 2026, then exercised 668 RSUs into common stock on June 2, 2026, increasing his direct share ownership.

How many CONMED (CNMD) shares does Charles Farkas hold after these transactions?

After exercising restricted stock units, Charles Farkas directly holds 15,527 shares of CONMED common stock. This figure reflects his position following the June 2, 2026 RSU conversion reported in the Form 4 insider filing.

What RSU grant did CONMED (CNMD) give to Charles Farkas in June 2026?

On June 1, 2026, CONMED granted Charles Farkas 5,772 restricted stock units. Each RSU represents a contingent right to receive one CONMED common share, generally vesting 100% after a one-year period under the 2025 Long-Term Incentive Plan.

How many CONMED (CNMD) RSUs did Farkas exercise and when?

On June 2, 2026, Farkas exercised 668 restricted stock units into 668 CONMED common shares. The exercise price is shown as $0.00 per share, and the RSU award involved no remaining balance after this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/03/2026 - 04:12 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farkas Charles

(Last)

(First)

(Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO

FLORIDA

33773

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/02/2026		M		668	A	$0	15,527	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
RSUs (Restricted Stock Units)	$0	06/01/2026		A		5,772		06/01/2027⁽¹⁾	06/01/2036	Common Stock	5,772	$0	5,772	D
RSUs (Restricted Stock Units)	$0	06/02/2026		M			668	06/02/2026⁽²⁾	06/02/2035	Common Stock	668	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.

	/s/ Thomas Fistek for Charles Farkas by Power of Attorney	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR